— Know what they know.
Not Investment Advice

RXST NASDAQ

RxSight, Inc.
1W: +5.1% 1M: +5.8% 3M: -18.5% YTD: -52.5% 1Y: -41.5% 3Y: -80.1% 5Y: -60.6%
$4.90
-0.03 (-0.61%)
After Hours: $5.27 (+0.37, +7.55%)
Weekly Expected Move ±5.8%
$4 $5 $5 $5 $6
NASDAQ · Healthcare · Medical - Devices · Tech Score Neutral · Power 47 · $203.8M mcap · 39M float · 2.54% daily turnover · Short 36% of daily vol
Credit Risk of going bust: lower than 57% of companies Debt: 4.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.3%), RxSight, Inc. would be worth roughly what it owes.
Total debt $10.6M against a stock market value of $205.1M.
Distance to default 5.81 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $5.3M (short-term plus half of long-term), stock volatility 62.5%; Altman Z -0.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$203.8M
52W Range4.4-13.22
Volume588,689
Avg Volume980,691
Beta1.14
Dividend—
Analyst Ratings
3 Buy 7 Hold 2 Sell
Consensus Hold
Company Info
CEOAziz Mottiwala
Employees461
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-07-30
100 Columbia
Aliso Viejo, CA 92656
US
949 521 7830
About RxSight, Inc.

As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.

Recent Insider Trades

NameTypeSharesPriceDate
Weinberg Eric M-Exempt 35,168 $4.34 2026-09-15
Weinberg Eric M-Exempt 35,168 $4.34 2026-09-15
Wilterding Mark D-Return 258,770 $10.09 2026-09-05
Wilterding Mark A-Award 258,770 $6.38 2026-09-05
Weinberg Eric D-Return 87,437 $16.00 2026-09-05

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms